FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130739618> ?p ?o ?g. }

• W3130739618 endingPage "1387" @default.
• W3130739618 startingPage "1379" @default.
• W3130739618 abstract "Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.Part 1 was open-label and Part 2 was randomised, double-blind, and placebo-controlled. Both required individualised dose escalation. Patients received nabiximols (Part 1, n = 6; Part 2, n = 12) or placebo (Part 2 only, n = 9); maximum of 12 sprays/day with DIT for up to 12 months. Safety, efficacy, and temozolomide (TMZ) pharmacokinetics (PK) were monitored.The most common treatment-emergent adverse events (TEAEs; both parts) were vomiting, dizziness, fatigue, nausea and headache. Most patients experienced TEAEs that were grade 2 or 3 (CTCAE). In Part 2, 33% of both nabiximols- and placebo-treated patients were progression-free at 6 months. Survival at 1 year was 83% for nabiximols- and 44% for placebo-treated patients (p = 0.042), although two patients died within the first 40 days of enrolment in the placebo arm. There were no apparent effects of nabiximols on TMZ PK.With personalised dosing, nabiximols had acceptable safety and tolerability with no drug-drug interaction identified. The observed survival differences support further exploration in an adequately powered randomised controlled trial.ClinicalTrials.gov: Part 1- NCT01812603; Part 2- NCT01812616." @default.
• W3130739618 created "2021-03-01" @default.
• W3130739618 creator A5021317857 @default.
• W3130739618 creator A5025749719 @default.
• W3130739618 creator A5029177787 @default.
• W3130739618 creator A5045895420 @default.
• W3130739618 creator A5077480031 @default.
• W3130739618 creator A5080160564 @default.
• W3130739618 creator A5084963696 @default.
• W3130739618 creator A5089518617 @default.
• W3130739618 date "2021-02-24" @default.
• W3130739618 modified "2023-10-06" @default.
• W3130739618 title "A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma" @default.
• W3130739618 cites W1566562478 @default.
• W3130739618 cites W1886084954 @default.
• W3130739618 cites W1977929532 @default.
• W3130739618 cites W1991238803 @default.
• W3130739618 cites W2027811460 @default.
• W3130739618 cites W2039149629 @default.
• W3130739618 cites W2091276673 @default.
• W3130739618 cites W2096287682 @default.
• W3130739618 cites W2100673960 @default.
• W3130739618 cites W2104958914 @default.
• W3130739618 cites W2129347432 @default.
• W3130739618 cites W2129406235 @default.
• W3130739618 cites W2137832651 @default.
• W3130739618 cites W2140381473 @default.
• W3130739618 cites W2147806499 @default.
• W3130739618 cites W2149768128 @default.
• W3130739618 cites W2155473143 @default.
• W3130739618 cites W2159661815 @default.
• W3130739618 cites W2160382843 @default.
• W3130739618 cites W2163264715 @default.
• W3130739618 cites W2164157263 @default.
• W3130739618 cites W2165138487 @default.
• W3130739618 cites W2168111104 @default.
• W3130739618 cites W2205491921 @default.
• W3130739618 cites W2279568831 @default.
• W3130739618 cites W2616653812 @default.
• W3130739618 cites W2618473238 @default.
• W3130739618 cites W2750624017 @default.
• W3130739618 cites W2756282134 @default.
• W3130739618 cites W2761862301 @default.
• W3130739618 cites W2778283729 @default.
• W3130739618 cites W2800242435 @default.
• W3130739618 cites W2801776207 @default.
• W3130739618 cites W2903049418 @default.
• W3130739618 cites W2914199948 @default.
• W3130739618 cites W3022913886 @default.
• W3130739618 cites W4212949515 @default.
• W3130739618 doi "https://doi.org/10.1038/s41416-021-01259-3" @default.
• W3130739618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8039032" @default.
• W3130739618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33623076" @default.
• W3130739618 hasPublicationYear "2021" @default.
• W3130739618 type Work @default.
• W3130739618 sameAs 3130739618 @default.
• W3130739618 citedByCount "50" @default.
• W3130739618 countsByYear W31307396182021 @default.
• W3130739618 countsByYear W31307396182022 @default.
• W3130739618 countsByYear W31307396182023 @default.
• W3130739618 crossrefType "journal-article" @default.
• W3130739618 hasAuthorship W3130739618A5021317857 @default.
• W3130739618 hasAuthorship W3130739618A5025749719 @default.
• W3130739618 hasAuthorship W3130739618A5029177787 @default.
• W3130739618 hasAuthorship W3130739618A5045895420 @default.
• W3130739618 hasAuthorship W3130739618A5077480031 @default.
• W3130739618 hasAuthorship W3130739618A5080160564 @default.
• W3130739618 hasAuthorship W3130739618A5084963696 @default.
• W3130739618 hasAuthorship W3130739618A5089518617 @default.
• W3130739618 hasBestOaLocation W31307396181 @default.
• W3130739618 hasConcept C126322002 @default.
• W3130739618 hasConcept C142724271 @default.
• W3130739618 hasConcept C143998085 @default.
• W3130739618 hasConcept C197934379 @default.
• W3130739618 hasConcept C204787440 @default.
• W3130739618 hasConcept C27081682 @default.
• W3130739618 hasConcept C2776694085 @default.
• W3130739618 hasConcept C2777389519 @default.
• W3130739618 hasConcept C2778375690 @default.
• W3130739618 hasConcept C2780580376 @default.
• W3130739618 hasConcept C42219234 @default.
• W3130739618 hasConcept C535046627 @default.
• W3130739618 hasConcept C71924100 @default.
• W3130739618 hasConcept C98274493 @default.
• W3130739618 hasConceptScore W3130739618C126322002 @default.
• W3130739618 hasConceptScore W3130739618C142724271 @default.
• W3130739618 hasConceptScore W3130739618C143998085 @default.
• W3130739618 hasConceptScore W3130739618C197934379 @default.
• W3130739618 hasConceptScore W3130739618C204787440 @default.
• W3130739618 hasConceptScore W3130739618C27081682 @default.
• W3130739618 hasConceptScore W3130739618C2776694085 @default.
• W3130739618 hasConceptScore W3130739618C2777389519 @default.
• W3130739618 hasConceptScore W3130739618C2778375690 @default.
• W3130739618 hasConceptScore W3130739618C2780580376 @default.
• W3130739618 hasConceptScore W3130739618C42219234 @default.
• W3130739618 hasConceptScore W3130739618C535046627 @default.
• W3130739618 hasConceptScore W3130739618C71924100 @default.
• W3130739618 hasConceptScore W3130739618C98274493 @default.

• next